Suzetrigine mechanism, efficacy, and clinical implications: A narrative review
Abstract
Acute pain, especially in postoperative and trauma areas, continues to be a substantial clinical problem all around the world, and this has been made worse by the opioid crisis as well as the drawbacks of the current non-opioid analgesics. The recent approval by the FDA of Suzetrigine (Journavx®) in January 2025 as the first-ever non-opioid analgesic aimed at the NaV1.8 sodium channel has opened new paths in pain management. Suzetrigine works only on NaV1.8 in the peripheral pain-sensing neurons, giving the patient targeted relief from pain without central nervous system (CNS) side effects or the risk of addiction. This paper sums up the newest clinical trial results (NAVIGATE-1 and NAVIGATE-2), real-world evidence, and regulatory frameworks to give a complete account of Suzetrigine’s pharmacology, clinical efficacy, safety profile, and potential to change acute pain treatment. While Suzetrigine showed a statistically significant and clinically relevant reduction in pain during Phase III trials, its use on a long-term basis for chronic pain and in other fields still has to be studied. This review furthermore evaluates the factors that make it difficult to approve such medicine, like doctors' education and the cost, and at the same time, it encourages the research and policy changes that will be needed to harness the full power of Suzetrigine.
Read the paper
Related studies
- Noninvasive and Point-of-Care Surface-Enhanced Raman Scattering (SERS)-Based Breathalyzer for Mass Screening of Coronavirus Disease 2019 (COVID-19) under 5 min
- De Novo Transcriptome Analysis and Detection of Antimicrobial Peptides of the American Cockroach Periplaneta americana (Linnaeus)
- Molecular Characterization and Expression Profiling of Tomato GRF Transcription Factor Family Genes in Response to Abiotic Stresses and Phytohormones
- Assembly of Tight Junction Strands: Claudin-10b and Claudin-3 Form Homo Tetrameric Building Blocks that Polymerise in a Channel-Independent Manner
- Update of the Pompe variant database for the prediction of clinical phenotypes: Novel disease‐associated variants, common sequence variants, and results from newborn screening
- Machine Learning-Based SERS Chemical Space for Two-Way Prediction of Structures and Spectra of Untrained Molecules
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.